TiGenix to discontinue cardiovascular pipeline

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said it will discontinue development of its allogeneic cardiovascular stem cell program, including AlloCSC-01, to focus on candidates derived from

Read the full 242 word article

User Sign In